Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | USP19 | O94966 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL28018953 | 0.87 | POLB (0.43) | POLBMEN1TSHRHTTKMT2A | |
| SCHEMBL20528485 | 0.87 | DPP4 (0.46) | POLBKMT2ADPP4DPP7RIPK1 | |
| SCHEMBL21801033 | 0.87 | DPP4 (0.46) | POLBKMT2ADPP4DPP7RIPK1 | |
| SCHEMBL2935422 | 0.87 | DPP4 (0.46) | POLBKMT2ADPP4DPP7RIPK1 | |
| SCHEMBL7749807 | 0.87 | RIPK1 (0.46) | DPP4DPP7RIPK1TAAR1USP19 | |
| SCHEMBL7590748 | 0.86 | POLB (0.42) | POLBMEN1TSHRHTTKMT2A | |
| SCHEMBL3338258 | 0.86 | LMNA (0.44) | POLBDPP4DPP7 | |
| Hydrochloric Acid SCHEMBL9258072 | 0.86 | DPP4 (0.46) | POLBKMT2ADPP4DPP7RIPK1 | |
| SCHEMBL19217307 | 0.85 | POLB (0.42) | POLBDPP4DPP7RIPK1TAAR1 | |
| SCHEMBL2386164 | 0.84 | DPP4 (0.47) | POLBDPP4DPP7RIPK1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353096-B2 | Substituted phenylcarbamate compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2310364-B1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC SRL (IT) | 2013-01-02 | — | — | EP | disclosed |
| EP-2310364-B1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC SRL (IT) | 2013-01-02 | — | — | EP | disclosed |
| US-20110105474-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.R.L. | 2011-05-05 | — | — | US | disclosed |
| US-20110105474-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.R.L. | 2011-05-05 | — | — | US | disclosed |
| US-20110105474-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.R.L. | 2011-05-05 | — | — | US | disclosed |
| EP-2310364-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.r.l. (IT) | 2011-04-20 | — | — | EP | disclosed |
| WO-2009150129-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.R.L. (IT) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150129-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | DAC S.R.L. (IT) | 2009-12-17 | — | — | WO | disclosed |
| EP-2133334-A1 | Heterocyclic derivatives as HDAC inhibitors | DAC S.r.l. (IT) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133334-A1 | Heterocyclic derivatives as HDAC inhibitors | DAC S.r.l. (IT) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218144-A1 | SUBSTITUTED PHENYLCARBAMATE COMPOUNDS | TRPA1, TRPV1, TRPV3 | POLB 4464/4885MEN1 3883/4885TSHR 3116/4885 |
| US-20110105474-A1 | HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS | HDAC3, HDAC1, HDAC5 | POLB 650/4885MEN1 2072/4885TSHR 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.